Home Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
|

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.

Print
Share

Also of interest

New mechanism of cortisone action deciphered

Sjögren-Tag 2024 am 6. April bei der Deutschen Rheuma-Liga Berlin

Sign up for the
DRFZ NewsFlash